Incomplete HPV vaccination among individuals aged 27-45 years in the United States: a mixed effect analysis of individual and contextual factors
Introduction
In the United States, the human papillomavirus (HPV) vaccine is approved for use in individuals up to age 45. Individuals 15 years and older require three doses of the vaccine to complete the recommended dosing series. Incomplete HPV vaccination rates (i.e., one or two doses) among those over age 26, however, remain high. This study examined the independent effects of individual- and neighborhood-level factors on incomplete HPV vaccination rates in the United States (U.S.) among those aged 27-45 years.
Methods
This retrospective cohort study used administrative data from Optum’s de-identified Clinformatics® Data Mart Database to identify individuals aged 27-45 years who received one or more doses of HPV vaccine between July 2019 and June 2022. Multilevel multivariable logistic regression models were applied to the data on 7,662 individuals identified as being fully or partially vaccinated against HPV, nested within 3.839 neighborhoods across the U.S.
Results
Approximately half of the patients in this study (52.93%) were not completely vaccinated against HPV. After adjusting for all other covariates in the final model, being older than 30 years old decreased the odds of not completing the HPV vaccine series. Participants living in South region neighborhoods of the U.S. had enhanced odds of not completing the vaccine series compared to those residing in Northeast region neighborhoods (aOR 1.21; 95% CrI 1.03–1.42). There was significant clustering of incomplete HPV vaccination rates at the neighborhood level.
Conclusion
This study revealed that individual- and neighborhood-level factors were associated with risk of not completing the HPV vaccine series among individuals aged 27-45 years in the U.S. Interventions to improve HPV vaccination series completion rates for this age group should take into consideration both individual and contextual factors.